CONMED Corp
No enriched coverage for $CNMD in the last 7 days.
No SEC Form 4 filings for $CNMD in the last 30 days.
See all $CNMD insider activity →CONMED (CNMD) shares rose 16% over the past month as investors weighed improved profitability and a raised 2026 earnings outlook. Q2 revenue was $343.5M (+0.3% YoY); gross margin rose to 57.5%. Adjusted EBITDA was $78.1M (22.7% margin). 2026 EPS guidance increased to $4.48-$4.60, but operating cash flow and free cash flow guidance were weaker.
CONMED (CNMD) trades at 10.82x forward 12-month earnings, below Zacks sub-industry (17.71x) and Medical sector (21.07x), and under its 5-year median (18.49x). Management raised 2026 adjusted EPS to $4.48-$4.60 from $4.30-$4.45 after Q2 results. Organic revenue excluding gastroenterology rose 6%. Execution and cash-flow risks remain.
CONMED (CNMD) raised its 2026 adjusted EPS outlook to $4.48-$4.60 from $4.30-$4.45 after better-than-expected Q2 results. Q2 adjusted EPS rose 20% to $1.38 and revenue was $343.5M. The company expects 2026 organic growth of 5%-6% and higher interest expense, with free cash flow guidance about $115M.
Recent CNMD coverage spans earnings, market movers and financial news.
Guidance lift and margin/EBITDA expansion are near-term bullish, but uneven AirSeal growth and weaker cash conversion temper follow-through.
Guidance lift improves near-term earnings visibility, but higher interest expense and lower free cash flow guidance keep execution risk elevated.
Raised EPS range is a near-term positive, but higher financing costs and a narrower organic growth outlook temper upside and keep the setup mixed.
The article frames CNMD as fundamentally improving via organic growth and product adoption, while emphasizing tariff-driven EPS risk that could cap upside.
Raised guidance after an earnings beat is likely to sustain upward momentum, but the move is already large intraday.
alphai scores every news story that mentions CNMD with an AI model for sentiment and relevance, and aggregates insider trades from CONMED Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
CONMED (CNMD) shares rose 16% over the past month as investors weighed improved profitability and a raised 2026 earnings outlook. Q2 revenue was $343.5M (+0.3% YoY); gross margin rose to 57.5%. Adjusted EBITDA was $78.1M (22.7% margin). 2026 EPS guidance increased to $4.48-$4.60, but operating cash flow and free cash flow guidance were weaker.
6 min readCONMED (CNMD) trades at 10.82x forward 12-month earnings, below Zacks sub-industry (17.71x) and Medical sector (21.07x), and under its 5-year median (18.49x). Management raised 2026 adjusted EPS to $4.48-$4.60 from $4.30-$4.45 after Q2 results. Organic revenue excluding gastroenterology rose 6%. Execution and cash-flow risks remain.
6 min readCONMED (CNMD) raised its 2026 adjusted EPS outlook to $4.48-$4.60 from $4.30-$4.45 after better-than-expected Q2 results. Q2 adjusted EPS rose 20% to $1.38 and revenue was $343.5M. The company expects 2026 organic growth of 5%-6% and higher interest expense, with free cash flow guidance about $115M.
6 min readZacks says CONMED (CNMD) is positioned for growth from higher adoption of products including AirSeal, Buffalo Filter and BioBrace, and expects at least 5% organic constant-currency growth in 2026. Risks include tariff headwinds, with management citing about a 35-cent-per-share EPS impact in 2026, and moderating AirSeal growth. CNMD projects 4.8% earnings growth over five years.
6 min readCONMED (NYSE: CNMD) shares rose about 10.5% after the company reported Q2 adjusted EPS of $1.38 versus $1.15 a year earlier and above the $1.11 analyst estimate. CONMED also topped revenue expectations and raised full-year adjusted EPS guidance to $4.54 (midpoint) and revenue to $1.37B.
6 min readCONMED (NYSE:CNMD) reported Q2 CY2026 revenue of $343.5 million, flat year over year but 1.8% above Wall Street estimates. The company guided full-year revenue to about $1.37 billion. Non-GAAP adjusted EPS was $1.38, 24.3% above consensus, and the stock rose 5.7% to $45.73 after the report.
6 min readCONMED Corp (CNMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cnmdearningsrelease06302026.htm EX-99.1 Document NEWS RELEASE CONTACT : CONMED Corporation Investor Relations ir@conmed.com CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance Largo, Florida, July 29, 2026 – CONMED Corporati
6 min readCONMED (NYSE: CNMD) shares rose about 9% after reports said the medical technology company is exploring a potential sale. The company is reportedly working with advisers to evaluate options, including a sale, after receiving interest from private equity firms. The article also notes BofA’s prior downgrade and revised 2027 growth and EPS estimates.
3 min readCONMED (NYSE:CNMD) shares fell about 4.9% after BofA Securities downgraded the stock to Underperform from Neutral, citing growth concerns. BofA cut its 2027 organic growth estimate to 4.5% from 5.8% and 2027 EPS to $4.54 from $4.67 (vs. $4.79 consensus), while keeping a $40 price target. Shares later traded around $34.26.
4 min readCONMED Corp (CNMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029501601ex10-1.htm LETTER AGREEMENT, DATED MAY 28, 2026, BY AND BETWEEN THE COMPANY AND JOHN E. GALLAGHER Exhibit 10.1 John D. Ferrell Executive Vice President, HR CONMED Corporation 11311 Concept Blvd. Largo, FL 33773 May 28, 2026 John Gallagher 331 Indian Trail Dri
3 min read
